Abstract: The invention provides animal models and clinical trials for assessing agents for potential use in treating and effecting prophylaxis stroke and other neurological diseases, particularly those mediated at least in part by excitoxitity. The invention also provides preferred dosage and infusion regimes and pharmaceutical compositions for clinical application of such agents.
Type:
Grant
Filed:
January 14, 2015
Date of Patent:
April 4, 2017
Assignee:
NoNO INC.
Inventors:
Michael Tymianski, Jonathan David Garman
Abstract: Disclosed herein are isolated polypeptides, antibody preparations, treatment methods, diagnostic methods, and screening methods related to tauopathy. Generally, the isolated polypeptide includes a core pentapeptide, with the proviso that the isolated polypeptide is not a native full-length tau protein. Generally, the antibody preparations include antibody that specifically binds to SEQ ID NO:12. Generally, the treatment methods include administering to a subject a composition that includes the isolated polypeptide. Generally, the diagnostic methods includes contacting a sample from a subject with an antibody preparation that includes antibody that specifically binds to SEQ ID NO:12, and then detecting a ligand in the sample that specifically binds the antibody preparation.
Type:
Grant
Filed:
November 23, 2015
Date of Patent:
March 28, 2017
Assignee:
Regents of the University of Minnesota
Inventors:
Karen Hsiao Ashe, Xiaohui Zhao, Michael Anthony Walters, Derek John Hook, Morgan Clotaire Paul Le Naour
Abstract: The present invention relates to a method for diagnosing a neurodegenerative disease in a subject, wherein the level of each of at least two catecholamines is measured in a sample of biological fluid from said subject.
Type:
Grant
Filed:
September 17, 2012
Date of Patent:
March 28, 2017
Assignees:
Centre National De La Recherche Scientifique (C.N.R.S), Universite Paris-Sud 11
Inventors:
Myriam Taverna, Romain Verpillot, Markus Otto, Hans Klafki
Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.
Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
Type:
Grant
Filed:
October 8, 2013
Date of Patent:
March 28, 2017
Assignee:
PROTHENA BIOSCIENCES LIMITED
Inventors:
Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
Abstract: Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
Type:
Grant
Filed:
December 20, 2013
Date of Patent:
March 21, 2017
Assignees:
Biogen MA Inc., Biogen International Neuroscience GmbH
Inventors:
Paul H. Weinreb, Feng Chen, Ellen A. Garber, Jan Grimm, Fabio Montrasio
Abstract: The present invention relates to anti-Tau antibodies, such as antibodies that bind to a phosphorylated epitope on human Tau protein with high specificity and/or affinity, and methods of using the same.
Type:
Grant
Filed:
March 12, 2014
Date of Patent:
March 21, 2017
Assignees:
AC IMMUNE S.A., GENENTECH, INC.
Inventors:
Gai Ayalon, Danielle Marie Di Cara, Isidro Hotzel, Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson
Abstract: Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Alzheimer's disease (AD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against AD.
Abstract: The described invention provides methods and kits for administering an EPO-derived peptide to a subject suffering from a neurodegenerative disease. The EPO-derived peptide delays the onset and/or progression of a neurodegenerative disease, limits cognitive impairment in, and prolongs the survival of, subjects suffering from a neurodegenerative disease.
Abstract: A method of detecting a disease associated with abnormal protein aggregation in a subject is provided, the method comprising (a) contacting leukocytes from the subject with a probe that binds to pathogenic protein aggregates, and (b) detecting the probe bound to the pathogenic protein aggregates, wherein the presence of pathogenic protein aggregates in the leukocytes is indicative that the subject has a disease associated with abnormal protein aggregation. In one embodiment, the disease is Alzheimer's disease or mild cognitive impairment.
Abstract: The present invention relates to a method for the diagnosis and/or risk stratification of neuromyelitis optica (abbreviated NMO), wherein a determination from a body sample of a patient/test subject is performed by means of artificial aquaporin-4 peptides. The invention further relates to a kit and to new artificial aquaporin-4 peptides as such.
Type:
Grant
Filed:
March 28, 2014
Date of Patent:
March 7, 2017
Assignee:
PROTAGEN AG
Inventors:
Heike Göhler, Petra Rengers, Angelika Lüking, Stefan Müllner
Abstract: Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include amyloid beta (A?), and the methods, agents and devices are useful for reducing the accumulation of A?, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to A?, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral antibodies to A?, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.
Type:
Grant
Filed:
May 22, 2015
Date of Patent:
February 28, 2017
Assignee:
Medtronic, Inc.
Inventors:
Lisa Lynn Shafer, Deepak Ramesh Thakker
Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.
Type:
Grant
Filed:
April 26, 2013
Date of Patent:
February 21, 2017
Assignees:
MDC Max-Delbruck-Centrum Fur Molekulare Medizin Berlin-Buch, Fresenius Medical Care Deutschland GmbH
Inventors:
Rudolf Kunze, Gerd Wallukat, Peter Rosenthal, Richard Straube
Abstract: Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.
Type:
Grant
Filed:
February 28, 2013
Date of Patent:
February 14, 2017
Assignees:
THE MCLEAN HOSPITAL CORPORATION, UNIVERSITY OF DELHI
Inventors:
Diwan S. Rawat, Sunny Manohar, Ummadisetty Chinna Rajesh, Deepak Kumar, Anuj Thakur, Mohit Tripathi, Panyala Linga Reddy, Shamseer Kulangara Kandi, Satyapavan Vardhineni, Kwang-Soo Kim, Chun-Hyung Kim
Abstract: Methods for treating or preventing tauopathies and/or A? amyloidosis by modulating CRF receptor signaling. Accumulation of hyperphosphorlyated tau protein in the CNS may be reduced by administration of CRF-R1 selective antagonists and/or CRF-R2 selective agonists. For example, in some aspects, methods for preventing the onset of Alzheimer's disease by administration of CRF-R1 selective antagonist are provided.
Type:
Grant
Filed:
June 13, 2008
Date of Patent:
January 31, 2017
Assignee:
Research Development Foundation
Inventors:
Robert A. Rissman, Kuo-Fen Lee, Wylie W. Vale, Paul E. Sawchenko
Abstract: The present invention generally provides methods and compositions for transdifferentiation of an animal cell from a first non-pluripotent cell fate to a second non-pluripotent cell fate. Also provided are methods and compositions for the transdifferentiation of an animal cell from a non-pluripotent mesodermal, endodermal, or ectodermal cell fate to a different non-pluripotent mesodermal, endodermal, or ectodermal cell fate.
Type:
Grant
Filed:
March 17, 2016
Date of Patent:
January 31, 2017
Assignee:
The Scripps Research Institute
Inventors:
Jem A. Efe, Janghwan Kim, Saiyong Zhu, Simon Hilcove, Sheng Ding
Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
Type:
Grant
Filed:
January 15, 2014
Date of Patent:
January 31, 2017
Assignee:
PROTHENA BIOSCIENCES LIMITED
Inventors:
José William Saldanha, Tarlochan S. Nijjar
Abstract: Assays for selecting a candidate modulator of a TMEM120A ion channel and/or a candidate modulator of chronic pain, the steps comprising contacting a lipid membrane comprising contacting a lipid membrane comprising TMEM120A polypeptide with a test compound; quantitating the TMEM120A ion channel activity; comparing the ion channel activity of the TMEM120A polypeptide with a control; and selecting the test compound that modulates the ion channel activity compared to the control; and methods and compositions for treating chronic pain including osteoarthritic pain.
Type:
Grant
Filed:
June 18, 2015
Date of Patent:
January 24, 2017
Assignee:
THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
Abstract: The present invention relates to a mitochondria targeting peptide, a fusion protein in which the peptide is bound to the carboxyl terminus of a protein transduction domain, a fusion protein in which the peptide is bound to the carboxyl terminus of a protein transduction domain and an antioxidant is bound to the carboxyl terminus of the peptide, an antioxidant composition and a composition for preventing or treating Parkinson's disease including the fusion protein in which the antioxidant is bound, a recombinant polynucleotide in which a polynucleotide coding a protein transduction domain, a polynucleotide coding the peptide, and a polynucleotide coding an antioxidant protein are sequentially bound, to an expression vector including the polynucleotide, and to a transformed host cell including the expression vector.
Type:
Grant
Filed:
August 30, 2013
Date of Patent:
January 10, 2017
Assignee:
UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
Inventors:
Young Mi Kim, Young Cheol Kang, Yong Hee Kim